Editorial, “The Menace From Avian Flu,”New York Times, October 12, 2004, at A-30.
2.
KolataG., “Genetic Material of Virus from 1918 Flu is Found,”New York Times, March 21, 1997, at A-2.
3.
StevensJ.CorperA.L.BaslerC.F.TaubenbergerJ.K.PaleseP., and WilsonI.A., “Structure of the Uncleaved Human H1 Hemagglutinin from the Extinct 1918 Influenza Virus,”Science303 (2004): 1866–70.
4.
BarryJ.M., The Great Influenza: The Epic Story of the Deadliest Plague in History (New York: Viking, 2004).
5.
Board on Global Health, Institute of Medicine, Learning from SARS: Preparing for the Next Disease Outbreak (Washington, DC: National Academies Press, 2004).
6.
BradshereK.AltmanL.K., “A War and a Mystery: Confronting Avian Flu,”New York Times, October 12, 2004, at D-1.
7.
Affected countries include Cambodia, China, Indonesia, Malaysia, Japan, Hong Kong, Laos, South Korea, Thailand, and Vietnam.
8.
Centers for Disease Control and Prevention, “Outbreaks of Avian Influenza A (H5N1) in Asia and Interim Recommendations for Evaluation and Reporting of Suspected Cases—United States,”Morbidity and Mortality Weekly Report53 (2004): 97–100.
9.
DaoJ., “Bird Flu Outbreak has Farmers Jittery,”New York Times, February 16, 2004, at A-12.
10.
Orders pursuant to 42 CFR 71–32b dated Feb. 4, March 10, and Sept. 28, 2004.
CDC, “Outbreaks in Asia,”at <http://www.cdc.gov/flu/avian/out-breaks/asia.htm> (last visited October 18, 2004); see MarkelH., When Germs Travel: Six Major Epidemics that Have Invaded America Since 1900 and the Fears They Have Unleashed (New York: Pantheon Books, 2004).
13.
TamPui-Wing, “Chiron Receives U.S. Subpoena Over Flu Vaccine,”The Wall Street Journal, October 13, 2004; AbejoJerry, “Chiron Target of Shareholder Lawsuit,”The Wall Street Journal, October 14, 2004.
14.
Levine, “District to Issue Emergency Order Limiting Flu Shots,”Washington Post, October 15, 2004, at B1; Haigh, “Bluementhal Wants Rell to Call Flu Vaccine Emergency,”Associated Press, October 14, 2004; Mulder, “Some Insurers Will Pay for FluMist,”The Post-Standard, October 14, 2004.
15.
Grady, “With Few Suppliers of Flu Shots, Shortage Was Long in Making,”New York Times, October 17, 2004.
16.
WebbyR. J. and WebsterR.G., “Are We Ready for Pandemic Influenza?”Science302 (2003): 1519–22; World Health Organization, WHO Consultation on Priority Public Health Interventions Before and During an Influenza Pandemic (Geneva, Switzerland: WHO, 2004); seeBoard on Global Health, Institute of Medicine, supra note 5.
17.
WeinsteinR.A., “Planning for Epidemics: The Lessons of SARS,”N. Engl. J. Med.350 (2004): 2332–34.
18.
McNeilD.G.Jr., “Experts Call Wild Birds Victims, Not Vectors,”New York Times, October 12, 2004, at D-6.
19.
EmanuelE.J., “Preventing the Next SARS”New York Times, May 12, 2003, at A-25.
20.
The Sanitary and Phytosanitary Measures Agreement is designed to promote free trade by ensuring that national measures to protect human, animal, or plant life are scientifically-based and not pretexts to protect domestic markets from international competition. See TaylorA.L.BettcherD.W.FlussS.S.DeLandK., and YachD., “International Health Instruments: An Overview,” in DetelsR.McEwenJ.BeagleholeR., and TanakaH., eds., Oxford Textbook of Public Health, 4th ed. (Oxford: Oxford University Press, 2002): At 359–86.
21.
GostinL.O.BayerR. and FairchildA.L., “Ethical and Legal Challenges Posed by Severe Acute Respiratory Syndrome: Implications for the Control of Severe Infectious Disease Threats,”JAMA290 (2003): 3229–37.
22.
WHO Secretariat, Revision of the International Health Regulations, Geneva, Switzerland: World Health Organization, January 15, 2004, Publication EB113/3 Rev. 1; see GostinL.O., “The International Health Regulations and Beyond,”The Lancet: Infectious Diseases4 (2004): 606–607.
23.
GostinL.O., “International Infectious Disease Law: Revision of the World Health Organization's International Health Regulations,”JAMA291 (2004): 2623–27
24.
BayerR.ToomeyK.E., “HIV Prevention and the Two Faces of Partner Notification,”American Journal of Public Health82 (1992): 1158–64.
25.
MitchellV.S.PhiliposeN.M., and SanfordJ.P., eds., The Children's Vaccine Initiative: Achieving the Vision (Washington, D.C.: National Academy Press, 1993); PearsonG.W., ed., The Children's Vaccine Initiative: Continuing Activities (Washington, D.C.: National Academy Press, 1995).
26.
BradshereK. and AltmanL.K., “Experts Confront Major Obstacles in Containing Virulent Bird Flu,”New York Times, September 30, 2004, at A-1.
27.
Committee on a Strategy for Minimizing the Impact of Naturally Occurring Infectious Diseases of Military Importance, Protecting Our Forces: Improving Vaccine Acquisition and Availability in the U.S. Military (National Academy Press, 2002).
28.
Statement from the IOM Council on Vaccine Development, November 5, 2001, available at <http://www.iom.edu/report.asp?id=5487> (last visited October 18, 2004).
29.
LonginiI.M.JrHalloranM.E.NizamA., and YangY., “Containing Pandemic Influenza with Antiviral Agents,”American Journal of Epidemiology159 (2004): 623–33.
30.
Jacobson v. Massachusetts, 197 U.S. 11 (1905); see GostinL.O., “Jacobson v. Massachusetts at 100: The Police Power and Civil Liberties in Tension,”American Journal of Public Health (Forthcoming 2005).
31.
SpierS.E., “Perception of Risk of Vaccine Adverse Events: A Historical Perspective,”Vaccine20, suppl. 1 (2001): S78–84.
32.
NeustadtR.FinebergH.V., The Epidemic That Never Was: Policy Making in the Swine Flu Scare (New York: Vintage Books, 1983).
33.
KraussC., “The SARS Epidemic: Toronto; Canada Increases Pressure on World Health Organization to Lift Travel Advisory,”New York Times, April 26, 2003, at A-8.
34.
Intergovernmental Working Group on the Revision of the International Health Regulations, World Health Organization, Working paper for regional consultations, Geneva (Switzerland): 2004.
35.
New York v. New St. Mark's Baths, 497 N.Y.S.2d 979 (1986).
36.
GostinL.O.SapsinJ.W.TeretS.P.BurrisS.MairJ.S.HodgeJ.G.Jr., and VernickJ. S., “The Model State Emergency Health Powers Act: Planning and Response to Bioterrorism and Naturally Occurring Infectious Diseases,”JAMA288 (2002): 622–628.
37.
GostinL.O., “Public Health Law in an Age of Terrorism: Rethinking Individual Rights and Common Goods,”Health Affairs21 (2002): 79–93.
38.
Greene v. Edwards, 263 S.E.2d 661 (W.Va. 1980).
39.
BarberaJ.MacintyreA.GostinL.O.InglesbyT.O'TooleT.DeAtleyC., “Large-Scale Quarantine Following Biological Terrorism in the United States: Scientific Examination, Logistic and Legal Limits, and Possible Consequences,”JAMA286 (2001): 2711–17.
40.
SapsinJ.W.ThompsonT.M.StoneL.DeLandK.E., “International Trade, Law, and Public Health Advocacy,”Journal of Law, Medicine & Ethics31 (2003): 546–56.
41.
GilmanS.L., “Disease and Stigma,”Lancet354, suppl. (1999): SIV15.
42.
GostinL.O., Public Health Law: Power, Duty, Restraint (Berkeley and New York: University of California Press and Milbank Memorial Fund, 2000).
43.
“The Siracusa Principles on the Limitation and Derogation Provisions in the International Covenant on Civil and Political Rights,”Human Rights Quarterly7 (1985): 3–14.